About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
Previous Close | $3.86 | Open | $3.85 |
Volume | 1.99M | Market Cap | 109.7M |
Yield | Last Dividend |
Moleculin Announces Full Exercise of Ove... | 02/10/21 |
HOUSTON, Feb. 10, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company... |
Moleculin Announces Grant Awarded to Pol... | 02/08/21 |
HOUSTON , Feb. 8, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (NASDAQ: MBRX ) (Moleculin or the Company), a clinical stage pharmaceutical company wi... |
Moleculin Announces Pricing Of $67.8 Mil... | 02/03/21 |
HOUSTON, Feb. 3, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company ... |
Moleculin to Present at the H.C. Wainwri... | 01/07/21 |
HOUSTON, Jan. 7, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with... |
Moleculin To Present Antitumor Activity ... | 12/03/20 |
HOUSTON, Dec. 3, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with... |
72 Biggest Movers From Yesterday | 12/02/20 |
Gainers Auris Medical Holding Ltd. (NASDAQ: EARS ) shares jumped 371% to close at $5.23 on Tuesday after the company reported positive efficacy data f... |
FDA Rare Pediatric tags for WP1066 lifts... | 12/01/20 |
Moleculin Biotech (NASDAQ:MBRX) soars 41% in premarket, after the FDA has designated Rare Pediatric Disease tag for its drug candidate WP1066, for eac... |
Thinking about buying stock in Titan Pha... | 12/01/20 |
NEW YORK, Dec. 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTNP, MRNA, MBRX, CRBP, and ALT. To see how InvestorsOb... |
Moleculin Biotech (NASDAQ:MBRX) Upgraded... | 11/20/20 |
Zacks Investment Research upgraded shares of Moleculin Biotech (NASDAQ:MBRX) from a hold rating to a buy rating in a research note released on Thursda... |
Moleculin Announces New Data Demonstrati... | 11/19/20 |
HOUSTON, Nov. 19, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company wit... |
Moleculin Biotech, Inc. Reports Financia... | 11/13/20 |
HOUSTON, Nov. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company wit... |
Moleculin to Participate in Panel at ROT... | 10/27/20 |
HOUSTON, Oct. 27, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company wit... |
Moleculin Announces Independent Study Va... | 10/21/20 |
HOUSTON, Oct. 21, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company wit... |
Moleculin Announces Additional Positive ... | 10/13/20 |
HOUSTON, Oct. 13, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company wit... |
Moleculin Announces New Antiviral Drug C... | 10/06/20 |
HOUSTON, Oct. 6, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with... |
Moleculin Appoints Elizabeth Cermak to B... | 10/05/20 |
HOUSTON, Oct. 5. 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with... |
Moleculin Announces Positive Interim Res... | 10/01/20 |
HOUSTON, Oct. 1, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with... |
Moleculin Announces Discovery of Signifi... | 09/29/20 |
HOUSTON, Sept. 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company wi... |
Moleculin Announces COVID-19 In Vivo Tes... | 09/14/20 |
HOUSTON, Sept. 14, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... |
Moleculin Announces Successful Completio... | 09/09/20 |
HOUSTON, Sept. 9, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company... |
Moleculin Biotech???s Antimetabolites CO... | 07/21/20 |
No summary available. |
Moleculin Pops 33% On Anti-Viral Activit... | 07/21/20 |
Moleculin Biotech (MBRX) on Tuesday announced that a second round of independent laboratory testing has confirmed the antiviral activity of its drug c... |
Thinking about buying stock in Moleculin... | 07/15/20 |
NEW YORK, July 15, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MBRX, VBIV, RIGL, DAL, and VSLR. To see how InvestorsO... |
Nasdaq Halts Moleculin Biotech Inc. | 05/18/20 |
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market?? (Nasdaq: NDAQ) announced that the trading halt status in Moleculin Biotech Inc???... |
Moleculin Biotech shares remain halted o... | 05/18/20 |
Moleculin Biotech Inc. undefined said Monday its shares remain halted on Nasdaq with the exchange seeking additional information from the company. Sha... |
Moleculin to Speak on COVID-19 Panel at ... | 04/29/20 |
HOUSTON, April 29, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... |
Moleculin Approved to Accelerate Europea... | 04/28/20 |
HOUSTON, April 28, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... |
Moleculin Biotech, Inc. (MBRX) Flat As M... | 04/27/20 |
Moleculin Biotech, Inc. (MBRX) closed the most recent trading day at $1.14, making no change from the previous trading session. |
Is Moleculin Biotech (MBRX) Stock Outpac... | 04/27/20 |
Is (MBRX) Outperforming Other Medical Stocks This Year? |
Moleculin Announces Agreement with ImQue... | 04/20/20 |
HOUSTON, April 20, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical compan... |
Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
Total Revenue | $1.3B | Total Liabilities | $2.1B |
Cost of Revenue | $2.5B | Total cash flow | $3.2 |
Total Assets | $29.98B |
% Insider | 12.52% | % Institutional | 76.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Service Name | Trader | % Success | |
---|---|---|---|
Big Data Zhou | Zhou Academy | 82.00 % | Subscribe |
MOJO SWING TRADE PICKS | ProTrader Mike | 61.00 % | Follow |
Mojo Day Trading | ProTrader Mike | 46.00 % | Subscribe |
R R Holding Company | Roland Van Rij | 11.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.